Systematic review maps pharmacogenomics-guided cardiovascular therapy in low- and middle-income countries
PLOS Global Public Health ·
What to know
A systematic review of 24 studies (2020–2025) found that genotype-guided warfarin dosing nearly quintupled time in therapeutic INR range versus standard care, and decision models supported cost-effectiveness of genotype-guided antiplatelet therapy. However, African-ancestry individuals comprised less than 1% of global PGx participants, and evidence certainty ranged from very low to moderate, with barriers including high testing costs, workforce shortages, and low physician genetic knowledge.
Source and evidence
PLOS Global Public HealthOriginal language · und ·Original author: Md. Farid Reza Mashfi, Sumiya Sharmin Mou, Monalisa Riya, Nasiba Binte Bahar, Tasnuha Islam, Fayek Rafi Ahmad, Fabliha Fatima, Md. Elias Al-Mamun · PLOS Global Public Health Readzer provides an abridged translation. CC-BY-4.0.Source licence
Why it matters by industry
- Healthcare & Life Sciences
Directly relevant to cardiovascular medicine and pharmacogenomics, providing a synthesized evidence base on efficacy, cost-effectiveness, and equity gaps in LMICs, which informs clinical implementation and public health policy.
Reviewed summary. The complete article remains at its original source.